Clinical Trial: Phase I Clinical Study to Evaluate the Safety and Efficacy of 3SC009 Monotherapy for Patients With Advanced Solid Tumors

U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07815002) titled 'Phase I Clinical Study to Evaluate the Safety and Efficacy of 3SC009 Monotherapy for Patients With Advanced Solid Tumors' on Aug. 18.

Brief Summary: This study includes two parts, different part has different administration frequencies of 3SC009.

Study Start Date: Sept. 30

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors Patients

Intervention: DRUG: 3SC009

A CD47/EpCAM bispecific antibody

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.

Published by HT Digital Content Services with permission from Health Daily Digest....